Abstract
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.
Keywords:
Diffuse large B-cell lymphoma; R-CHOP; SIL index; prognosis; soluble interleukin-2 receptor.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lactate Dehydrogenases / blood*
-
Lymphoma, Large B-Cell, Diffuse / blood*
-
Lymphoma, Large B-Cell, Diffuse / diagnosis*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Prognosis
-
Receptors, Interleukin-2 / blood*
-
Rituximab
-
Survival Analysis
-
Treatment Outcome
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
-
Young Adult
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Biomarkers
-
R-CHOP protocol
-
Receptors, Interleukin-2
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Lactate Dehydrogenases
-
Prednisone